Mayne Pharma introduces a capsule formulation for its migraine product
Mayne Pharma is unveiling its butalbital acetaminophen (APAP) capsule in a 50-mg/300-mg dosage strength.
This is a new capsule formulation of butalbital/APAP, which is indicated for the treatment of tension headache or migraine. Mayne Pharma currently markets butalbital/APAP tablets in a 50-mg/300-mg dosage strength.
"We are pleased to bring this new capsule formulation to market providing alternative treatment options to patients who previously only had a tablet option," Mayne Pharma’s CEO Scott Richards said. "This new product is highly complementary to our butalbital/APAP/caffeine tablet and capsule portfolio, which are also used to treat migraines. Mayne Pharma continues to expand its product portfolio through internal product development, in-licensing, acquisition and working collaboratively with partners."
This is a new capsule formulation of butalbital/APAP, which is indicated for the treatment of tension headache or migraine. Mayne Pharma currently markets butalbital/APAP tablets in a 50-mg/300-mg dosage strength.
"We are pleased to bring this new capsule formulation to market providing alternative treatment options to patients who previously only had a tablet option," Mayne Pharma’s CEO Scott Richards said. "This new product is highly complementary to our butalbital/APAP/caffeine tablet and capsule portfolio, which are also used to treat migraines. Mayne Pharma continues to expand its product portfolio through internal product development, in-licensing, acquisition and working collaboratively with partners."